ACHL Stock Overview
A biopharmaceutical company, develops precision T cell therapies to treat solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Achilles Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.98 |
| 52 Week High | US$1.76 |
| 52 Week Low | US$0.63 |
| Beta | 1.37 |
| 1 Month Change | -8.31% |
| 3 Month Change | -5.66% |
| 1 Year Change | 19.60% |
| 3 Year Change | -82.39% |
| 5 Year Change | n/a |
| Change since IPO | -94.07% |
Recent News & Updates
Recent updates
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Feb 26Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 13Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Jul 19Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
Mar 11Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Nov 18Achilles-led group gets €4M funding for personalized cell therapy manufacturing
Jul 21Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?
Apr 13Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans
Dec 27Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation
Sep 09Shareholder Returns
| ACHL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.9% | -5.6% | -3.5% |
| 1Y | 19.6% | -1.5% | 22.1% |
Return vs Industry: ACHL exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: ACHL underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| ACHL volatility | |
|---|---|
| ACHL Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACHL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACHL's weekly volatility has decreased from 9% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Iraj Ali | www.achillestx.com |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Achilles Therapeutics plc Fundamentals Summary
| ACHL fundamental statistics | |
|---|---|
| Market cap | US$40.28m |
| Earnings (TTM) | -US$66.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs ACHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$66.88m |
| Earnings | -US$66.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACHL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Achilles Therapeutics plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Ingrid Gafanhão | Bryan Garnier & Co |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |